Solabegron zwitterion and uses thereof
This application relates to solabegron zwitterion useful for the treatment of lower urinary tract symptoms such as, for example, overactive bladder and prostate disorders. Additionally, this application relates to pharmaceutical compositions and methods of treatment utilizing the solabegron zwitterion for treating lower urinary tract symptoms. This application also relates to methods of preparing solabegron hydrochloride from the solabegron zwitterion.
1. An isolated compound according to Formula II:
or a pharmaceutically acceptable salt or stereoisomer thereof, in the form of a hydrated isopropanol solvate.
2. The isolated compound according to claim 1 , wherein the isolated compound is a crystalline solid.
3. The isolated compound according to claim 1 , wherein the compound is at least about 97.0% by weight pure.
4. The isolated compound according to claim 1 , wherein the compound is at least about 99.0% by weight pure.
5. The isolated compound according to claim 1 , wherein the compound is at least about 99.5% by weight pure.
6. The isolated compound according to claim 1 , wherein the compound is at least about 99.9% by weight pure.
7. The isolated compound according to claim 1 , wherein no single impurity is present in an amount greater than about 0.5% by weight.
8. The isolated compound according to claim 1 , wherein no single impurity is present in an amount greater than about 0.25% by weight.
9. The isolated compound according to claim 1 , wherein no single impurity is present in an amount greater than about 0.10% by weight.
10. The compound of claim 1 wherein the hydrated isopropanol solvate is 3 equivalents of the compound of Formula II:1 equivalent of isopropanol:2 equivalents water.
11. A pharmaceutical composition comprising: a therapeutically effective amount of a solid compound according to Formula II:
or a pharmaceutically acceptable salt or stereoisomer, in the form of a hydrate of isopropanol solvate; and
at least one pharmaceutically acceptable carrier or excipient.
12. The composition according to claim 11 , further comprising one or more additional therapeutic agents selected from the group consisting of: antimuscarinic agents; alpha adrenoceptor blockers; 5-alpha reductases; and phosphodiesterases-5 inhibitors.
13. The pharmaceutical composition of claim 11 wherein the hydrated isopropanol solvate is 3 equivalents of the compound of Formula II:1 equivalent of isopropanol:2 equivalents water.